Insider Selling: Lantheus Holdings, Inc. (NASDAQ:LNTH) CFO Sells 5,000 Shares of Stock

Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating) CFO Robert J. Jr. Marshall sold 5,000 shares of the company’s stock in a transaction dated Wednesday, March 15th. The shares were sold at an average price of $71.58, for a total value of $357,900.00. Following the completion of the sale, the chief financial officer now owns 128,298 shares in the company, valued at approximately $9,183,570.84. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Lantheus Price Performance

Lantheus stock opened at $77.84 on Friday. The stock has a market capitalization of $5.26 billion, a price-to-earnings ratio of 228.94 and a beta of 0.64. Lantheus Holdings, Inc. has a 52-week low of $47.46 and a 52-week high of $87.47. The company has a debt-to-equity ratio of 1.25, a quick ratio of 2.59 and a current ratio of 2.74. The stock’s 50 day moving average price is $62.11 and its two-hundred day moving average price is $63.82.

Lantheus (NASDAQ:LNTHGet Rating) last issued its earnings results on Thursday, February 23rd. The medical equipment provider reported $1.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $0.41. Lantheus had a net margin of 3.00% and a return on equity of 51.60%. The business had revenue of $263.17 million for the quarter, compared to analyst estimates of $244.61 million. On average, equities analysts predict that Lantheus Holdings, Inc. will post 4.46 earnings per share for the current year.

Institutional Trading of Lantheus

Large investors have recently made changes to their positions in the company. CWM LLC raised its stake in Lantheus by 82.1% during the 3rd quarter. CWM LLC now owns 366 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 165 shares during the period. Wipfli Financial Advisors LLC acquired a new position in shares of Lantheus during the third quarter worth approximately $30,000. Wolverine Asset Management LLC bought a new position in shares of Lantheus in the 4th quarter worth $36,000. Coppell Advisory Solutions Corp. acquired a new stake in Lantheus in the 4th quarter valued at $48,000. Finally, Globeflex Capital L P increased its stake in Lantheus by 10,600.0% during the 4th quarter. Globeflex Capital L P now owns 1,070 shares of the medical equipment provider’s stock valued at $55,000 after purchasing an additional 1,060 shares in the last quarter. 97.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LNTH has been the topic of several analyst reports. JMP Securities started coverage on Lantheus in a report on Wednesday, March 8th. They issued an “outperform” rating and a $120.00 target price on the stock. SVB Leerink initiated coverage on shares of Lantheus in a research note on Wednesday, November 30th. They issued an “outperform” rating on the stock. Mizuho increased their price objective on shares of Lantheus from $105.00 to $115.00 and gave the stock a “buy” rating in a research report on Friday, February 24th. Finally, started coverage on shares of Lantheus in a report on Thursday. They issued a “hold” rating on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

About Lantheus

(Get Rating)

Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.

Featured Stories

Insider Buying and Selling by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with's FREE daily email newsletter.